Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 4 Cost-effectiveness results of base case

From: Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective

Treatment regimen

Total costs

QALYs

Incremental cost per QALY gained

DEX (SOC)

R 8 312

1.14

 

BORT

R 234 995

1.49

R 654 649

LEN/DEX

R 1 135 323

2.22

R 1 225 542